NL-OMON48473已完成不适用
A PHASE 1 TRIAL TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, AND PHARMACOKINETICS OF 14C-E7727 IN HEALTHY VOLUNTEERS >=65 YEARS OF AGE - [14C]-E7727 Mass Balance study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Gender: male or female; females must be postmenopausal
- •2. Age: >=65 years, at screening.
- •3. Body mass index (BMI): 18.0 to 32.0 kg/m2, inclusive.
- •4. Status: healthy subjects
- •5. Male subjects, if not surgically sterilized, with a female partner of childbearing potential must agree to use adequate contraception and not donate sperm from first admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence, in accordance with the lifestyle of the subject, is also acceptable.
- •6. All prescribed medication must have been stopped at least 30 days prior to each admission to the clinical research center.
- •7. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John*s Wort) must have been stopped at least 14 days prior to each admission to the clinical research center. An exception is made for paracetamol, which is allowed up to each admission to the clinical research center.
- •8. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, soft drinks, chocolate, energy drinks), and grapefruit (juice) and tobacco products from 48 hours prior to each admission to the clinical research center.
- •9. Satisfactory physical and mental health on the basis of medical history, physical examination, clinical laboratory, 12-lead electrocardiogram (ECG), and vital signs, as judged by the PI.
- •10. Willing and able to sign the ICF.
- •11. Subject is able to understand and comply with the study procedures and understands the risks involved in the study
排除标准
- •1. Employee of PRA or the Sponsor.
- •2. History of relevant drug and/or food allergies.
- •3. Using tobacco products and/or alcohol in the 48 hours (2 days) prior to first admission to the clinical research center is not allowed.
- •4. Known significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator predisposes the subject to high risk of noncompliance with the protocol.
- •5. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol ) at screening and each admission to the clinical research center.
- •6. Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
- •7. Positive screen for hepatitis B surface antigen (HBsAg), antihepatitis C virus (HCV) antibodies, or antihuman immunodeficiency virus (HIV) 1 and 2 antibodies.
- •8. Participation in an investigational drug study within 60 days prior to the first drug administration in the current study. Participation in more than 4 other drug studies in the year prior to the first drug administration in the current study.
- •9. Donation or loss of more than 100 mL of blood within 60 days prior to the first drug administration. Donation or loss of more than 1.5 liters of blood (for male subjects)/more than 1.0 liter of blood (for female subjects) in the 10 months prior to the first drug administration in the current study.
- •10. Significant and/or acute illness within 5 days prior to the first drug administration that may impact safety assessments, in the opinion of the Investigator.
- •11. Unsuitable peripheral veins for infusion or blood sampling.
- •12. Participation in another ADME study with a radiation burden >0.1 mSv in the period of 1 year prior to screening.
- •13. Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton [excluding spinal column]), during work, or during participation in a clinical study in the period of 1 year prior to screening.
- •14. Irregular defecation pattern (less than once per 2 days).
研究者
相似试验
已完成
不适用
A Phase 1 Trial to Assess the Mass Balance, Absolute Bioavailability, and Pharmacokinetics of 14C ASTX660 in Healthy Volunteerssolid tumors, lymphomaadvanced solid tumors10024324lymphomaNL-OMON49455Astex Pharmaceuticals, Inc.8
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Absolute Bioavailability, and Pharmacokinetics of 14C-ASTX029 in Healthy Volunteersadvanced solid tumorssolid tumorsNL-OMON51576Astex Pharmaceuticals, Inc.8
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14C]-GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Healthy Participantssickle cell disease10038158sickle cell anemiaNL-OMON53865Global Blood Therapeutics, Inc.9
尚未招募
不适用
A Phase 1 Trial to Assess the Mass Balance and Pharmacokinetics of 14C-Guadecitabine in Subjects with AML, MDS, or Solid Tumorsblood- and bone marrow cancer10024324NL-OMON46860Astex Pharmaceuticals, Inc6
进行中（未招募）
1 期
OP-724-001 studyHealthy volunteersJPRN-jRCT2031230432Yuushi Haruyama6